Valuation : Ryvu Therapeutics S.A.

Market Cap 402M 108M 92.84M 87.33M 79.56M 150M 10.21B 150M 1.03B 5.2B 404M 395M 17.23B P/E 2026 *
-8.44x
P/E 2027 * -7.74x
Enterprise Value 371M 99.27M 85.63M 80.55M 73.38M 138M 9.42B 139M 952M 4.79B 373M 365M 15.89B EV / Sales 2026 *
2.71x
EV / Sales 2027 * 5.28x
Free-Float
64.97%
Yield 2026 *
-
Yield 2027 * -
1 day-1.70%
1 week-5.54%
Current month-1.70%
1 month+17.91%
3 months+9.45%
6 months-34.04%
Current year-35.87%
1 week 17.1
Extreme 17.1
18.48
1 month 14.66
Extreme 14.66
19.58
Current year 13.64
Extreme 13.64
28.95
1 year 13.64
Extreme 13.64
31.9
3 years 13.64
Extreme 13.64
72.4
5 years 13.64
Extreme 13.64
72.4
10 years 13.64
Extreme 13.64
78
Manager TitleAgeSince
Chief Executive Officer - 2006-12-31
Chief Tech/Sci/R&D Officer - 2022-01-31
Chief Operating Officer 41 2020-11-22
Director TitleAgeSince
Chairman - 2018-12-31
Director/Board Member 75 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
4/15/26 Sell

Executive/Senior Manager

2,500 0.0108%
4/15/26 Sell

Executive/Senior Manager

5,000 0.0216%
4/15/26 Sell

Executive/Senior Manager

5,000 0.0216%
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-5.54%-37.71%-71.46% 110M
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+0.80%+46.29%+85.32% 63.6B
+1.31%-5.21%+37.52%+12.07% 25.57B
-0.25%-1.92%-10.72%+436.70% 26.6B
+0.33%-10.61%+1.95%-16.27% 25.52B
-6.09%-12.08%+226.11%+375.00% 18.23B
+1.18%-2.23%+30.87%-19.04% 19.69B
-1.49%-6.44%+0.78%+540.26% 15.16B
+4.12%+0.30%+52.03%+150.18% 13.54B
Average -0.16%-4.06%+39.66%+158.22% 27.62B
Weighted average by Cap. +0.15%-2.88%+45.19%+143.79%

Financials

2026 *2027 *
Net sales 137M 36.57M 31.54M 29.67M 27.03M 50.83M 3.47B 51.11M 351M 1.77B 137M 134M 5.85B 82.97M 22.22M 19.17M 18.03M 16.43M 30.89M 2.11B 31.06M 213M 1.07B 83.43M 81.62M 3.56B
Net income 13.35M 3.58M 3.08M 2.9M 2.64M 4.97M 339M 5M 34.3M 173M 13.42M 13.13M 572M -66.37M -17.78M -15.33M -14.42M -13.14M -24.71M -1.69B -24.84M -171M -858M -66.74M -65.29M -2.85B
Net Debt -31.2M -8.36M -7.21M -6.78M -6.18M -11.62M -793M -11.68M -80.16M -403M -31.37M -30.69M -1.34B 35.89M 9.61M 8.29M 7.8M 7.11M 13.36M 912M 13.43M 92.21M 464M 36.09M 35.31M 1.54B
Logo Ryvu Therapeutics S.A.
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Employees
228
Date Price Change Volume
26-09-01 PLN 17.38 -1.70% 28,925
26-08-31 PLN 17.68 -3.81% 21,035
26-08-28 PLN 18.38 0.00% 8,043
26-08-27 PLN 18.38 -0.65% 12,179
26-08-26 PLN 18.50 +0.54% 37,983
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
17.38PLN
Average target price
33.62PLN
Spread / Average Target
+93.44%

Quarterly revenue - Rate of surprise